Timeline

Marie-Anne Rameix-Welti

Head of Structure

01 Apr 2025

project

Proposed approach to evaluate the potential of avian influenza viruses of concern to undergo genetic reassortment and acquire an MxA-resistant NP segment

20 Feb 2025

project

Monitor French respiratory virus epidemics using phylodynamics methods

01 Jan 2025

publication

Monitoring SARS-CoV-2 variants with complementary surveillance systems: risk evaluation of the Omicron JN.1 variant in France, August 2023 to January 2024.

01 Jan 2025

publication

Preparedness, prevention and control related to zoonotic avian influenza.

24 Dec 2024

publication

Performance of whole genome sequencing for respiratory syncytial virus: insights from the first external quality assessment, France, 2024.

19 Nov 2024

publication

Antagonism of BST2/Tetherin, a new restriction factor of respiratory syncytial virus, requires the viral NS1 protein

01 Nov 2024

publication

Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.

14 Oct 2024

publication

Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.

01 Oct 2024

publication

Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.

25 Jul 2024

publication

Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.

30 Jun 2024

project

Accounting for defective genomes in virus consensus reconstruction

08 Feb 2024

publication

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.

01 Jan 2024

publication

Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies.

01 Jan 2024

publication

Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus.

01 Jan 2024

publication

Novel scores relevant to antimicrobial resistance and hospital-acquired infections developed with data from a multi-hospital consortium in the Parisian region of France.

30 Sep 2023

project

Seq4Epi: Sequencing pathogens for epidemiology

08 Sep 2023

publication

Hardening of Respiratory Syncytial Virus Inclusion Bodies by Cyclopamine Proceeds through Perturbation of the Interactions of the M2-1 Protein with RNA and the P Protein.

19 Jan 2023

project

RSV virion release mechanisms

19 Jan 2023

project

RSV ribonucleoproteins export mechanisms

19 Jan 2023

project

Towards the elucidation of the morphogenesis, organization and functioning of respiratory syncytial virus factories

04 Jan 2023

team

Molecular mechanisms of multiplication of Pneumoviruses M3P

01 Jan 2023

publication

Ribonucleoprotein transport in Negative Strand RNA viruses.

01 Jan 2023

publication

Spatial resolution of virus replication: RSV and cytoplasmic inclusion bodies.

20 Dec 2022

publication

Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages.

13 Dec 2022

publication

Retinoic Acid-Inducible Gene I Activation Inhibits Human Respiratory Syncytial Virus Replication in Mammalian Cells and in Mouse and Ferret Models of Infection.

01 Jul 2022

publication

Respiratory syncytial virus ribonucleoproteins hijack microtubule Rab11 dependent transport for intracellular trafficking.

01 Apr 2022

publication

Sensitive visualization of SARS-CoV-2 RNA with CoronaFISH.

31 Mar 2022

project

AURORAE: Laboratory Support for SARS-CoV-2, influenza and RSV for Europe

01 Oct 2021

publication

Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients.

01 Oct 2021

publication

Monocyte distribution width as a biomarker of resistance to corticosteroids in patients with sepsis: the MOCORSEP observational study.

01 Jul 2021

publication

Pulmonary mesenchymal stem cells are engaged in distinct steps of host response to respiratory syncytial virus infection.

01 Jul 2021

publication

A condensate-hardening drug blocks RSV replication in vivo.

12 Feb 2021

publication

Molecular investigation of a RSV outbreak in a geriatric hospital.

28 Jan 2021

publication

New Look at RSV Infection: Tissue Clearing and 3D Imaging of the Entire Mouse Lung at Cellular Resolution.

01 Jan 2021

publication

Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis.

01 Nov 2020

publication

Clinical Cutaneous Features of Patients Infected With SARS-CoV-2 Hospitalized for Pneumonia: A Cross-sectional Study.

22 Sep 2020

publication

Minimal Elements Required for the Formation of Respiratory Syncytial Virus Cytoplasmic Inclusion Bodies In Vivo and In Vitro.

01 Sep 2020

publication

Respiratory syncytial virus tropism for olfactory sensory neurons in mice.

29 Jul 2020

publication

Regulatory B Lymphocytes Colonize the Respiratory Tract of Neonatal Mice and Modulate Immune Responses of Alveolar Macrophages to RSV Infection in IL-10-Dependant Manner.

15 May 2020

publication

De novo protein design enables the precise induction of RSV-neutralizing antibodies.

01 May 2020

publication

Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.

01 Jan 2020

publication

A small fragmented P protein of respiratory syncytial virus inhibits virus infection by targeting P protein.

01 Jan 2020

publication

Single-Stranded Oligonucleotide-Mediated Inhibition of Respiratory Syncytial Virus Infection.

24 Oct 2019

publication

The Interactome analysis of the Respiratory Syncytial Virus protein M2-1 suggests a new role in viral mRNA metabolism post-transcription.

01 Sep 2019

publication

High-throughput screening of active compounds against human respiratory syncytial virus.

10 May 2019

publication

Destabilization of the human RED-SMU1 splicing complex as a basis for host-directed antiinfluenza strategy.

04 Apr 2019

publication

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses.

01 Feb 2019

publication

Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen.

01 Jan 2019

publication

Evaluation of the Antiviral Activity of Sephin1 Treatment and Its Consequences on eIF2α Phosphorylation in Response to Viral Infections

01 Mar 2018

publication

RSV hijacks cellular protein phosphatase 1 to regulate M2-1 phosphorylation and viral transcription.

01 Feb 2018

publication

Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice.

01 Feb 2018

publication

Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism.

15 Sep 2017

publication

Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus.

01 Apr 2017

publication

A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.

21 Feb 2017

publication

Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity.

01 Feb 2017

publication

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

27 Jul 2015

nrc

Viruses of Respiratory Infections (including Influenza and SARS-CoV-2)

01 Apr 2015

publication

Fine mapping and characterization of the L-polymerase-binding domain of the respiratory syncytial virus phosphoprotein.

15 Jan 2015

publication

Interactome analysis of the human respiratory syncytial virus RNA polymerase complex identifies protein chaperones as important cofactors that promote L-protein stability and RNA synthesis.

07 Jan 2015

publication

Identification and characterization of the binding site of the respiratory syncytial virus phosphoprotein to RNA-free nucleoprotein.

03 Oct 2014

publication

Visualizing the replication of respiratory syncytial virus in cells and in living mice.

21 Nov 2012

publication

Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility.

01 Sep 2011

publication

Influenza virus ribonucleoprotein complexes gain preferential access to cellular export machinery through chromatin targeting.

10 Aug 2011

publication

Influenza virus infection induces the nuclear relocalization of the Hsp90 co-chaperone p23 and inhibits the glucocorticoid receptor response.

01 Apr 2011

publication

Monitoring epidemic viral respiratory infections using one-step real-time triplex RT-PCR targeting influenza A and B viruses and respiratory syncytial virus.

01 Jan 2011

publication

Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution.

16 Nov 2010

publication

Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase.

01 Feb 2010

publication

Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.

30 Dec 2009

publication

Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA).

01 Sep 2009

publication

Influenza A virus neuraminidase enhances meningococcal adhesion to epithelial cells through interaction with sialic acid-containing meningococcal capsules.

18 Feb 2009

publication

Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice.

19 Nov 2008

publication

Avian Influenza A virus polymerase association with nucleoprotein, but not polymerase assembly, is impaired in human cells during the course of infection.

25 Jul 2008

publication

Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir.

01 Jan 2008

publication

Host restriction of avian influenza viruses at the level of the ribonucleoproteins.

01 May 2007

publication

Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited.

31 Jan 2007

publication

Host-range determinants on the PB2 protein of influenza A viruses control the interaction between the viral polymerase and nucleoprotein in human cells.

01 Jan 2007

publication

Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus.

28 Aug 2006

publication

Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.

26 Mar 2005

publication

A little guide for advanced search:

Proposed approach to evaluate the potential of avian influenza viruses of concern to undergo genetic reassortment and acquire an MxA-resistant NP segment

Monitor French respiratory virus epidemics using phylodynamics methods

Monitoring SARS-CoV-2 variants with complementary surveillance systems: risk evaluation of the Omicron JN.1 variant in France, August 2023 to January 2024.

Preparedness, prevention and control related to zoonotic avian influenza.

Performance of whole genome sequencing for respiratory syncytial virus: insights from the first external quality assessment, France, 2024.

Antagonism of BST2/Tetherin, a new restriction factor of respiratory syncytial virus, requires the viral NS1 protein

Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.

Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.

Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.

Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.

Accounting for defective genomes in virus consensus reconstruction

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.

Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies.

Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus.

Novel scores relevant to antimicrobial resistance and hospital-acquired infections developed with data from a multi-hospital consortium in the Parisian region of France.

Seq4Epi: Sequencing pathogens for epidemiology

Hardening of Respiratory Syncytial Virus Inclusion Bodies by Cyclopamine Proceeds through Perturbation of the Interactions of the M2-1 Protein with RNA and the P Protein.

RSV virion release mechanisms

RSV ribonucleoproteins export mechanisms

Towards the elucidation of the morphogenesis, organization and functioning of respiratory syncytial virus factories

Molecular mechanisms of multiplication of Pneumoviruses M3P

Ribonucleoprotein transport in Negative Strand RNA viruses.

Spatial resolution of virus replication: RSV and cytoplasmic inclusion bodies.

Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages.

Retinoic Acid-Inducible Gene I Activation Inhibits Human Respiratory Syncytial Virus Replication in Mammalian Cells and in Mouse and Ferret Models of Infection.

Respiratory syncytial virus ribonucleoproteins hijack microtubule Rab11 dependent transport for intracellular trafficking.

Sensitive visualization of SARS-CoV-2 RNA with CoronaFISH.

AURORAE: Laboratory Support for SARS-CoV-2, influenza and RSV for Europe

Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients.

Monocyte distribution width as a biomarker of resistance to corticosteroids in patients with sepsis: the MOCORSEP observational study.

Pulmonary mesenchymal stem cells are engaged in distinct steps of host response to respiratory syncytial virus infection.

A condensate-hardening drug blocks RSV replication in vivo.

Molecular investigation of a RSV outbreak in a geriatric hospital.

New Look at RSV Infection: Tissue Clearing and 3D Imaging of the Entire Mouse Lung at Cellular Resolution.

Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis.

Clinical Cutaneous Features of Patients Infected With SARS-CoV-2 Hospitalized for Pneumonia: A Cross-sectional Study.

Minimal Elements Required for the Formation of Respiratory Syncytial Virus Cytoplasmic Inclusion Bodies In Vivo and In Vitro.

Respiratory syncytial virus tropism for olfactory sensory neurons in mice.

Regulatory B Lymphocytes Colonize the Respiratory Tract of Neonatal Mice and Modulate Immune Responses of Alveolar Macrophages to RSV Infection in IL-10-Dependant Manner.

De novo protein design enables the precise induction of RSV-neutralizing antibodies.

Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.

A small fragmented P protein of respiratory syncytial virus inhibits virus infection by targeting P protein.

Single-Stranded Oligonucleotide-Mediated Inhibition of Respiratory Syncytial Virus Infection.

The Interactome analysis of the Respiratory Syncytial Virus protein M2-1 suggests a new role in viral mRNA metabolism post-transcription.

High-throughput screening of active compounds against human respiratory syncytial virus.

Destabilization of the human RED-SMU1 splicing complex as a basis for host-directed antiinfluenza strategy.

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses.

Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen.

Evaluation of the Antiviral Activity of Sephin1 Treatment and Its Consequences on eIF2α Phosphorylation in Response to Viral Infections

RSV hijacks cellular protein phosphatase 1 to regulate M2-1 phosphorylation and viral transcription.

Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice.

Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism.

Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus.

A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.

Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity.

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

Viruses of Respiratory Infections (including Influenza and SARS-CoV-2)

Fine mapping and characterization of the L-polymerase-binding domain of the respiratory syncytial virus phosphoprotein.

Interactome analysis of the human respiratory syncytial virus RNA polymerase complex identifies protein chaperones as important cofactors that promote L-protein stability and RNA synthesis.

Identification and characterization of the binding site of the respiratory syncytial virus phosphoprotein to RNA-free nucleoprotein.

Visualizing the replication of respiratory syncytial virus in cells and in living mice.

Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility.

Influenza virus ribonucleoprotein complexes gain preferential access to cellular export machinery through chromatin targeting.

Influenza virus infection induces the nuclear relocalization of the Hsp90 co-chaperone p23 and inhibits the glucocorticoid receptor response.

Monitoring epidemic viral respiratory infections using one-step real-time triplex RT-PCR targeting influenza A and B viruses and respiratory syncytial virus.

Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution.

Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase.

Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.

Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA).

Influenza A virus neuraminidase enhances meningococcal adhesion to epithelial cells through interaction with sialic acid-containing meningococcal capsules.

Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice.

Avian Influenza A virus polymerase association with nucleoprotein, but not polymerase assembly, is impaired in human cells during the course of infection.

Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir.

Host restriction of avian influenza viruses at the level of the ribonucleoproteins.

Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited.

Host-range determinants on the PB2 protein of influenza A viruses control the interaction between the viral polymerase and nucleoprotein in human cells.

Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus.

Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.

[Neisseria meningitidis infection. Clinical criteria orienting towards a deficiency in the proteins of the complement].